• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

David A. Krendel, MD
The Emory Clinic Section of Neurology 1365 Clifton Road, NE Atlanta, GA 30322

Arch Neurol. 1996;53(7):591-592.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In reply

Walk describes another patient with a clinical syndrome consistent with PDN who improved after receiving IV immune globulin. This is encouraging and supports our impression that IV immune globulin can be an effective treatment in these patients.¹

The questions raised by Walk are important, and I appreciate the opportunity to offer my views.

• Do patients with diabetes and treatable neuropathies represent subsets of PDN and DDSPN with an unusually prominent secondary inflammatory response, or do they represent a distinct disease or group of diseases?

In my view, these explanations are not mutually exclusive. An unusually prominent secondary inflammatory response that causes widespread tissue damage and responds to immunosuppressive therapy can be viewed as a distinct autoimmune disease. Perhaps exposure of peripheral nerve antigens to the immune system predisposes patients with DDSPN to CIDP. Dyck et al² proposed a similar mechanism for prednisone-responsive neuropathy in patients . . . [Full Text PDF of this Article]

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?